Investment Highlights

BIOMARK INVESTMENT HIGHLIGHTS

Investment Highlights CSE Symbol BUX • FSE Symbol: 20B • OTCMKTS Symbol: BMKDF

  • TECHNOLOGY SUMMARY & STATUS

  • Our research is developing proprietary, non-invasive, highly accurate solutions to cost-effectively detect cancer in its very early stages, when approximately 90% of cancers can be cured

  • BioMark’s initial assay detects SSAT1, an enzyme with elevated levels in numerous cancers, using an FDA approved drug

  • Core focus on diagnostics for lung cancer, with plans to expand into breast, prostate, GI and ovarian cancers

  • Completed >200 patient trial; obtained extension of study from Health Canada for an additional 300 patients

     

  • 2017 VALUE DRIVERS

  • Global next generation cancer diagnostic market is anticipated to reach USD $20.25 billion by 2022

  • Metabolite-based tests have the potential to become the standard of care due to better detection vs. traditional biomarkers, thereby allowing for a diagnosis well before symptom occurrence

  • Potential to generate multiple revenue streams from product supply sales, lab analysis royalties, territorial and distribution licensing revenue and companion diagnostics services revenue to drug companies developing oncology therapeutics

  • Proven leadership with hand-picked, global enterprise team of scientist, engineers, regulatory and medical professionals

BioMark™ Value

BioMark-Investor-Relations

Target Market Focus

BioMark-Investor-Relations

How We Conduct Our Test (SSAT1 Assay)
– Convenient & Non Invasive

BioMark - How We Conduct Our Test

Test Delivery Options – SSAT1 Assay

LC MS Based System – READY TO MARKET

  • ITA secured
  • SOP established
  • Reference lab/Hospital

ELISA KIT

  • Antibody generated and optimized
  • Reference lab/Hospital

POINT OF CARE

  • Antibody generated and optimized
  • Prototype is under development
  • Health Care Center/Home